查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495997

全球酵素結合免疫吸附檢測法(ELISA) 市場 - 2024 年至 2029 年預測

Global Enzyme-Linked Immunosorbent Assay (ELISA) Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 135 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

酵素結合免疫吸附檢測法(ELISA) 市場預計將以 5.56% 的複合年成長率成長，從 2022 年的 21.38 億美元增至 2029 年的 31.23 億美元。

ELISA（酵素結合免疫吸附檢測法）或酵素免疫分析法測定（EIA）是一種基於板的測量技術，旨在檢測和定量勝胜肽、蛋白質、抗體和荷爾蒙等物質。 ELISA 通常用作更詳細測試之前的篩檢工具。由於 ELISA 反應物固定在微孔盤表面，因此在測定過程中可以輕鬆分離結合和未結合的物質。這使其成為測定粗製劑中特定分析物的強大工具。

ELISA 的常見診斷用途包括 HIV 感染、懷孕檢測和蛋白質檢測。預計 ELISA 市場在預測期內將穩定成長。這種成長可能是由於感染疾病和慢性病患病率的上升以及對 ELISA 作為具有成本效益的診斷工具的需求。然而，有關 ELISA 的嚴格監管要求和不利的報銷政策可能會阻礙預測期內的市場成長。

市場促進因素：

  • 感染疾病日益流行預計將推動市場成長。

推動市場擴張的關鍵因素之一是愛滋病毒、肝炎、瘧疾、登革熱和流感等感染疾病率的上升。世界衛生組織估計，到 2021年終，全球有 3,840 萬名愛滋病毒感染者，其中三分之二以上居住在非洲。世界衛生組織也聲稱，登革熱是世界面臨的十大健康威脅之一。過去 50 年來，全球登革熱發生率增加了約 3,000%。世界衛生組織也估計，2019 年全球有超過 2.96 億人感染B型肝炎。

由於感染疾病發生率不斷增加，對診斷的需求預計也會增加。由於擴大使用尖端診斷技術（例如酵素結合免疫吸附測試）來篩檢這些疾病，預計該市場將會擴大。

此外，全球越來越多的老年人患有感染疾病和慢性病的高風險並需要常規診斷，預計將刺激市場擴張。根據 NCBI（美國生物技術資訊中心）於 2021 年發布的消息，與年輕人相比，老年患者更有可能發生潛在危險的疾病。因此，這些因素預計將增加對酵素結合免疫吸附檢測法的需求，從而顯著提高市場成長。

  • 疾病診斷領域預計將大幅推動市場成長。

擴大使用酵素結合免疫吸附測定測試來診斷特定抗原，預計將佔據疾病診斷市場的重要佔有率。世界衛生組織估計，到 2022 年，非傳染性疾病每年將導致約 4,100 萬人死亡，佔全球死亡人數的 71%。此類疾病的發生增加了對有效診斷技術（例如用於快速檢測的 ELISA）的需求，以最大限度地降低死亡率。

此外，根據全球癌症觀察站的數據，2020年將有約1,930萬人新診斷出癌症，約1,000萬人將死於癌症。由於 ELISA 是評估抗原的有用工具，全球癌症發生率的上升正在推動其需求。

根據 Nature Scientific 2020 年的一項研究，酵素結合免疫吸附檢測法可用於尋找乳腺癌和前列腺癌抗原。這種準確的抗原篩檢和具有成本效益的診斷預計將在分析期間增加 ELISA 需求並推動市場擴張。

預計北美將佔據很大的市場佔有率

由於ELISA等篩檢設備技術突破的市場開拓迅速，美國很可能主導全球市場。該地區多種感染疾病和慢性疾病的發生率不斷增加，增加了對酵素酵素結合免疫吸附檢測法的需求。例如，美國疾病管制與預防中心 (CDC) 報告稱，到 2022 年，超過 60% 的美國人將患有至少一種慢性疾病，例如癌症、心血管疾病或中風。

由於研發支出的增加和診斷資金的大量投入，預計該地區的市場將會成長。根據 Binder Dijker Otte USA 2020 年報告，生技指數中的上市公司 2020 年研發支出平均成長約 16% 至 2.8425 億美元。

此外，2021 年，美國衛生與公眾服務部宣布從美國救援計畫中撥款 6.5 億美元，用於提高快速、高品質診斷測試的生產能力。因此，所有這些方面預計將在預測期內很好地支持北美區域市場。

主要發展

  • 2022 年 9 月 - Neogen Corporation 推出了用於腰果檢測的 Veratox VIP 測定法，作為其增強型定量 ELISA 系列的第二部分。無論樣品類型如何，這種創新測試都能提供穩健的性能，並保持 Veratox 產品線的簡單測試方法。 Neogen 旨在透過提供高度靈敏的測試來保護世界各地的消費者，這些測試甚至可以檢測出最低水平的食品過敏原。此測試對低至 0.2 ppm 的腰果蛋白水平具有很高的特異性。 Veratox VIP for Cashew 使用與現有 Veratox 產品線相同的測試方法，可在 30 分鐘內提供結果，並且還包括即用型無害試劑。
  • 2022 年 9 月 - J Mitra 推出 HCV Gen 4 Ag &Ab Microlisa，這是第四代基於 ELISA 的 HCV 測試。這種體外定性 ELISA 可檢測人類血清或血漿中的 HCV 核心抗原和 HCV 抗體。此檢測旨在幫助早期發現慢性HCV感染，與第三代檢測相比，將急性感染的窗口期縮短5至7週。此測試對於高風險族群和同時感染 HIV/HCV 的患者特別有用。 ELISA 測試具有高靈敏度和特異性，批次處理可實現快速週轉時間。 J Mitra 在改善印度丙肝診斷方面發揮關鍵作用。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行概述

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章酵素結合免疫吸附檢測法(ELISA) 全球市場：依類型

  • 介紹
  • 間接ELISA
  • 夾心ELISA
  • 競爭性ELISA

第6章酵素結合免疫吸附檢測法（ELISA）全球市場：依應用

  • 介紹
  • 飲食
  • 疫苗開發
  • 免疫學
  • 診斷
  • 藥物監測
  • 其他

第7章酵素結合免疫吸附檢測法(ELISA) 全球市場：依最終使用者分類

  • 介紹
  • 製藥業
  • 醫院和診所
  • 診斷中心
  • 其他

第8章酵素結合免疫吸附檢測法（ELISA）全球市場：按地區

  • 介紹
  • 北美洲
  • 南美洲
  • 歐洲
  • 中東/非洲
  • 亞太地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Pestka Biomedical Laboratories, Inc.
  • Diaclone SAS
  • Thermo Fisher Scientific Inc.
  • Azure Biosystems Inc.
  • R&D Systems, Inc
  • RayBiotech, Inc.
  • Elabscience
  • BioLegend, Inc.
  • Randox Toxicology
  • STEMCELL Technologies Inc.
  • Genway Biotech, Inc.
簡介目錄
Product Code: KSI061611695

The global Enzyme-Linked Immunosorbent Assay (ELISA) market is projected to grow at a CAGR of 5.56% increasing from US$2.138 billion in 2022 to US$3.123 billion in 2029.

ELISA (enzyme-linked immunosorbent assay) or enzyme immunoassay (EIA) is a plate-based assay technique designed for detecting and quantifying substances such as peptides, proteins, antibodies, and hormones. ELISA is often used as a screening tool before further in-depth tests are ordered. Reactants of the ELISA are immobilized to the microplate surface, making it easy to separate bound from non-bound material during the assay. This makes it a powerful tool for measuring specific analytes within a crude preparation.

The common diagnostic applications of ELISA are HIV infection, pregnancy tests, detection of proteins, etc. The ELISA market is expected to show robust growth during the forecast period. The growth may be attributed to the rising incidence of infectious and chronic diseases, which require ELISA as a cost-effective diagnostic tool. However, stringent regulatory requirements, as well as unfavorable reimbursement policies about ELISA, might hamper the market growth during the given time frame.

Market Drivers:

  • The rising prevalence of infectious diseases is predicted to propel the market growth.

One of the key drivers fuelling the market's expansion is the rising prevalence of infectious diseases like HIV, Hepatitis, malaria, dengue, and influenza, among other ailments. At the end of 2021, the WHO estimated that there were 38.4 million HIV-positive individuals worldwide, with more than two-thirds of them living in Africa. The WHO also claimed that dengue fever was among the top ten health threats facing the world. Over the past 50 years, dengue incidences have increased by about 3000% worldwide. WHO also estimated that more than 296 million individuals worldwide have hepatitis B infection as of 2019.

The demand for diagnosis is anticipated to rise as a result of the rising occurrence of infectious diseases. The market is anticipated to expand due to the rising use of cutting-edge diagnostic techniques for screening these disorders, such as enzyme-linked immunosorbent tests.

Additionally, the growing geriatric population, which is globally at risk of contracting illnesses and chronic diseases and requires routine diagnosis, is anticipated to fuel market expansion. In comparison to younger individuals, potentially dangerous illnesses are more likely in elderly patients, according to the NCBI (National Center for Biotechnology Information), which published this information in 2021. Thus, it is anticipated that these factors will considerably raise the market's growth by boosting demand for enzyme-linked immunosorbent assays.

  • The disease diagnosis segment is anticipated to surge the market growth.

Due to the growing use of enzyme-linked immunosorbent assay tests for the diagnosis of specific antigens, a sizable share of the disease diagnosis market has been predicted. In 2022, the WHO estimated that non-communicable illnesses caused around 41 million deaths each year, equivalent to 71% of all deaths worldwide. Due to these occurrences, there is now a greater need for efficient diagnostic techniques like ELISA for prompt detection to minimize death occurrences.

Additionally, according to the Global Cancer Observatory, there were approximately 19.3 million new cases of cancer and nearly 10.0 million cancer deaths worldwide in 2020. As ELISA is a useful instrument for assessing antigens, the rise in cancer incidence around the world is driving up demand for it.

The Enzyme-Linked Immunosorbent Assay can be used to find both breast cancer antigens and prostate cancer antigens, according to a 2020 Nature Scientific study. Such accurate antigen screening and cost-effective diagnosis are anticipated to boost ELISA demand and drive the market's expansion during the analyzed period.

North America is Expected to Hold a Significant Share in the Market

Because of the rapid development of technological breakthroughs in screening instruments like ELISA, the US is likely to dominate the global market. The increasing incidences of multiple infectious and chronic diseases in this demography are contributing to the strong demand for Enzyme-Linked Immunosorbent Assay. For instance, the CDC (Centre for Ailment Control and Prevention) reported in 2022 that over 60% of Americans had at least one chronic disease, such as cancer, cardiovascular disease, or stroke.

The market in this region is anticipated to grow as a result of rising R&D expenditures as well as numerous funding initiatives for diagnostics. Listed firms on the biotechnology index expanded their R&D spending by about 16% on average in 2020 to USD 284.25 million in the US, based on the Binder Dijker Otte USA Reports from 2020.

Additionally, in 2021, the Department of Health and Human Services said that it would deploy USD 650 million from the American rescue plan to increase production capabilities for swift, high-quality diagnostic tests. Therefore, it is projected that all of these aspects will support the North American regional market well over the predicted period.

Key Developments:

  • September 2022- Neogen Corporation introduced its Veratox VIP assay for cashew detection, the second in its enhanced quantitative ELISA line. This innovative test offers robust performance across sample types and maintains the simple testing methodology of the Veratox product line. Neogen aims to offer highly sensitive tests that can detect even the lowest levels of food allergens, protecting consumers worldwide. The test demonstrates a high level of specificity to very low levels of cashew protein, down to 0.2 ppm. The Veratox VIP for Cashew uses the same testing methodology as its existing Veratox product line, including a 30-minute time-to-result and ready-to-use, non-hazardous reagents.
  • September 2022- J Mitra introduced the HCV Gen 4 Ag & Ab Microlisa, a 4th Generation Elisa-based HCV test. This in-vitro qualitative ELISA detects HCV core antigens and antibodies against HCV in human serum or plasma. The test is designed to help detect chronic HCV infections early, reducing the window period for acute infection by 5-7 weeks compared to the 3rd generation test. The test is particularly useful in high-risk groups and HIV/HCV co-infected patients. The Elisa test offers higher sensitivity and specificity, and batch processing can result in a quick turnaround time. J Mitra has played a significant role in improving HCV diagnosis in India.

Segmentation:

By Type

  • Indirect ELISA
  • Sandwich ELISA
  • Competitive ELISA

By Application

  • Food and Beverage
  • Vaccine Development
  • Immunology
  • Diagnosis
  • Drug Monitoring
  • Others

By End Users

  • Pharmaceutical Industries
  • Hospitals and Clinics
  • Diagnostic Centres
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa (MEA)
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Indirect ELISA
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Sandwich ELISA
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Competitive ELISA
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness

6. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Food and Beverage
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Vaccine Development
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Immunology
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Diagnosis
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Drug Monitoring
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness
  • 6.7. Others
    • 6.7.1. Market Opportunities and Trends
    • 6.7.2. Growth Prospects
    • 6.7.3. Geographic Lucrativeness

7. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET BY END USERS

  • 7.1. Introduction
  • 7.2. Pharmaceutical Industries
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Hospitals and Clinics
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Diagnostic Centres
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Others
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness

8. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End Users
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Application
    • 8.3.3. By End Users
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Application
    • 8.4.3. By End Users
    • 8.4.4. By Country
      • 8.4.4.1. UK
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Italy
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Spain
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
      • 8.4.4.6. Others
        • 8.4.4.6.1. Market Opportunities and Trends
        • 8.4.4.6.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Application
    • 8.5.3. By End Users
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Application
    • 8.6.3. By End Users
    • 8.6.4. By Country
      • 8.6.4.1. Japan
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. China
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. Australia
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. South Korea
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Indonesia
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Thailand
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Taiwan
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects
      • 8.6.4.9. Others
        • 8.6.4.9.1. Market Opportunities and Trends
        • 8.6.4.9.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Pestka Biomedical Laboratories, Inc.
  • 10.2. Diaclone SAS
  • 10.3. Thermo Fisher Scientific Inc.
  • 10.4. Azure Biosystems Inc.
  • 10.5. R&D Systems, Inc
  • 10.6. RayBiotech, Inc.
  • 10.7. Elabscience
  • 10.8. BioLegend, Inc.
  • 10.9. Randox Toxicology
  • 10.10. STEMCELL Technologies Inc.
  • 10.11. Genway Biotech, Inc.